Tzvi Palash

Mr. Palash offers over 35 years of experience in the healthcare industry to Enlivex and has extensive expertise leading the construction of pharmaceutical manufacturing plants. Mr. Palash joined Enlivex from Gamida Cell where, as Chief Operating Officer (COO), he was responsible for overseeing operational activities including the recently completed construction of a cell therapy manufacturing plant. Prior to that, Mr. Palash was the COO of Protalix Biotherapeutics, Inc., where he led all operational activities through the approval of Elelyso®, the company’s plant cell culture-derived protein product, by the U.S. Food and Drug Administration (FDA). Prior to joining Protalix, Mr. Palash led the planning, construction, scale-up and regulatory oversight of an Israel-based manufacturing facility as a COO and General Manager at ColBar LifeScience Ltd, a biomaterials company acquired by Johnson & Johnson. He also successfully led FDA audits for Evolence® and Ossix®, and was a member of the Global Aesthetic Management Team within the Consumer Group of Johnson & Johnson. Earlier in his career, Mr. Palash held operational roles at Teva Pharmaceutical Industries and Interpham Laboratories.